June 3-5, 2023
The ASCO Annual Meeting brought together one of the world’s largest, most diverse audiences in global cancer care – cancer professionals from 150 different countries encompassing all oncology subspecialties. With the goal of leading the delivery of information and diverse expertise needed by the global oncology community, ASCO focuses on research, education, and promotion of the highest quality, most equitable patient care through its resolute mission to reduce the burden of cancer for all.
The TriSalus Team was proud to be a part of this year’s ASCO Annual Meeting, where we presented early response and safety information from the TS-PERIO-01 trial.
April 14-19, 2023
The AACR Annual Meeting brought together an enthusiastic and inspiring assembly of scientists, clinicians, biotech professionals, survivors, and patients to share the latest advances in cancer research and medicine. As the first and largest cancer research organization dedicated to accelerating the conquest of cancer, AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.
TriSalus was proud to contribute to the 2023 meeting with a poster presentation showing the initial safety experience and immunologic effects of SD-101 +/- checkpoint inhibition from our TS-PERIO-01 trial.
March 4-9, 2023
The SIR Annual Scientific Meeting brings together experts from across the interventional radiology community to discuss advancements in research and clinical practice. As a proud member of SIR’s Corporate Ambassador Program, TriSalus hosted several educational events and presented multiple research abstracts at this year’s conference.
January 19-23, 2023
During the Society of Interventional Oncology (SIO) 2023 Annual Scientific Meeting, TriSalus Chief Medical Officer, Dr. Steven Katz, along with Scientific Advisory Board Members Drs. Alexander Kim and Rahul Sheth, led a symposium discussing updates from the PERIO™ clinical trials. TriSalus Senior Director of Pharmacology and Therapeutics, Thomas Hullinger, presented pre-clinical data on the delivery of investigational SD-101 into pig liver tumors via Pressure-Enabled Drug Delivery™ (PEDD™) compared to a standard end-hole catheter.
January 19-21, 2023
At the 2023 ASCO Gastrointestinal (GI) Cancers Symposium, pre-clinical research, conducted in partnership with the UC San Diego Moores Cancer Center, was presented. The poster presentation demonstrated the benefits of Pressure-Enabled Drug Delivery™ (PEDD™) of an investigational TLR9 agonist in combination with checkpoint inhibitor therapy for the treatment of pancreatic tumors in murine models.
TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.
Thank you for visiting our site.